Transplant Genomics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
905 S Main St Ste 102, Mansfield, Massac...Phone Number
(781) 454-6523Website
www.transplantgenomics.comRevenue
$18.6 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Transplant Genomics
Eurofins Transplant Genomics is dedicated to enhancing organ transplant outcomes through noninvasive molecular diagnostic tests that identify early signs of graft injury and differentiate actionable causes. Their services include tests for kidney and liver transplants, such as TruGraf and OmniGraf, aimed at optimizing therapy and monitoring for acute rejection. The company targets clinicians, patients, and caregivers, providing educational resources and support for effective transplant management. By leveraging genetic biomarkers, they strive to improve patient care and transplant success rates.Explore more
Transplant Genomics Org Chart
LN
Regional Sales Manager, Transplant Southeast
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Transplant Genomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Transplant Genomics has new funding data
Click to see if Transplant Genomics had a recent Job posting/layoffs
Transplant Genomics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Transplant Genomics
Check out if Transplant Genomics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Transplant Genomics launches new products
Earning: See what the market has to say on Transplant Genomics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Transplant Genomics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Transplant Genomics
Find 3 more new buyers
Compare Similar Companies to Transplant Genomics
Compare insights from companies similar to Transplant Genomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$22.2M
51-200
Private
$10M
2015
AD
Alicia DillardAssociate Clinical Laboratory Director and Molecular Pathologist
Company Profile Activity
Activity Insights
Transplant Genomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Transplant Genomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Transplant Genomics.
Transplant Genomics financials insights
Gather financial insights about Transplant Genomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$2.8M
Private Equity
$3.2M
2015
Debt
$1.2M
2016
Debt
$530K
Debt
$1.7M
2017
Private Equity
$3.2M
Transplant Genomics Tech Stack
A closer look at the technologies used by Transplant Genomics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Research & Development, Medical Research, Clinical Operations, Healthcare Technology
Partnership
Partnership, Clinical Systems, Product Management, Sales Development
New Hire
Transplant Genomics News & Media
TRANSPLANT GENOMICS WELCOMES CHIEF MEDICAL OFFICER JON FRIEDMAN, MD, FAST
FRAMINGHAM, Mass., Feb. 1, 2022 /PRNewswire/ -- Transplant Genomics ("TGI"), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, welcomes Jon Friedman, MD, FAST as Chief Medical Officer of the company, effective January 31, 2022. Dr....American Journal Of Transplantation Article Validates Clinical Utility Of Donor-Derived Cell-Free DNA In Detecting Liver Rejection
FRAMINGHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Transplant Genomics ("TGI"), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, announces that the American Journal of Transplantation ("AJT") has published "Donor-Derived Cell-Free DNA...Transplant Genomics Enrolls 500th Patient In TRULO Observational Study
FRAMINGHAM, Mass., Nov. 1, 2021 /PRNewswire/ -- Transplant Genomics ("TGI"), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, today is pleased to announce that over 500 patients have been enrolled in the TRULO ("TruGraf Long-Term...Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients
LUXEMBOURG--(BUSINESS WIRE)--Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to introduce OmniGraf™, which combines the TruGraf® blood gene expression test and Viracor TRAC® donor-derived cell-free DNA assays. For renal transplant recipients, OmniGraf™ Kidney represents the first diagnostic tool that combines cell free DNA and gene expression data. When combined with TGI’s proprietary technology and
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Transplant Genomics
Sign Up For FreeTo access detailed company insights
Eurofins Transplant Genomics is dedicated to enhancing organ transplant outcomes through noninvasive molecular diagnostic tests that identify early signs of graft injury and differentiate actionable causes. Their services include tests for kidney and liver transplants, such as TruGraf and OmniGraf, aimed at optimizing therapy and monitoring for acu... Read More
